These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 30852338)

  • 1. Large-scale compound screens and pharmacogenomic interactions in cancer.
    McDermott U
    Curr Opin Genet Dev; 2019 Feb; 54():12-16. PubMed ID: 30852338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Pursuit of Therapeutic Biomarkers with High-Throughput Cancer Cell Drug Screens.
    Williams SP; McDermott U
    Cell Chem Biol; 2017 Sep; 24(9):1066-1074. PubMed ID: 28736238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomic biomarkers for personalized cancer treatment.
    Rodríguez-Antona C; Taron M
    J Intern Med; 2015 Feb; 277(2):201-217. PubMed ID: 25338550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional-genetic approaches to understanding drug response and resistance.
    Hinterndorfer M; Zuber J
    Curr Opin Genet Dev; 2019 Feb; 54():41-47. PubMed ID: 30951975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying synthetic lethal targets using CRISPR/Cas9 system.
    Dhanjal JK; Radhakrishnan N; Sundar D
    Methods; 2017 Dec; 131():66-73. PubMed ID: 28710008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional genomics approaches to improve pre-clinical drug screening and biomarker discovery.
    Nguyen LV; Caldas C
    EMBO Mol Med; 2021 Sep; 13(9):e13189. PubMed ID: 34254730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilizing yeast chemogenomic profiles for the prediction of pharmacogenomic associations in humans.
    Silberberg Y; Kupiec M; Sharan R
    Sci Rep; 2016 Mar; 6():23703. PubMed ID: 27025271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-Scale Signatures of Gene Interaction from Compound Screens Predict Clinical Efficacy of Targeted Cancer Therapies.
    Jiang P; Lee W; Li X; Johnson C; Liu JS; Brown M; Aster JC; Liu XS
    Cell Syst; 2018 Mar; 6(3):343-354.e5. PubMed ID: 29428415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in functional genetic screening with transposons and CRISPR/Cas9 to illuminate cancer biology.
    O'Donnell KA
    Curr Opin Genet Dev; 2018 Apr; 49():85-94. PubMed ID: 29587177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-throughput genetic screens using CRISPR-Cas9 system.
    Kweon J; Kim Y
    Arch Pharm Res; 2018 Sep; 41(9):875-884. PubMed ID: 29637495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells.
    Meyers RM; Bryan JG; McFarland JM; Weir BA; Sizemore AE; Xu H; Dharia NV; Montgomery PG; Cowley GS; Pantel S; Goodale A; Lee Y; Ali LD; Jiang G; Lubonja R; Harrington WF; Strickland M; Wu T; Hawes DC; Zhivich VA; Wyatt MR; Kalani Z; Chang JJ; Okamoto M; Stegmaier K; Golub TR; Boehm JS; Vazquez F; Root DE; Hahn WC; Tsherniak A
    Nat Genet; 2017 Dec; 49(12):1779-1784. PubMed ID: 29083409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR/Cas9 Editing to Facilitate and Expand Drug Discovery.
    Robert F; Huang S; Pelletier J
    Curr Gene Ther; 2017; 17(4):275-285. PubMed ID: 29173168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical genetics: Drug screens in Zebrafish.
    den Hertog J
    Biosci Rep; 2005; 25(5-6):289-97. PubMed ID: 16307377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stepwise group sparse regression (SGSR): gene-set-based pharmacogenomic predictive models with stepwise selection of functional priors.
    Jang IS; Dienstmann R; Margolin AA; Guinney J
    Pac Symp Biocomput; 2015; 20():32-43. PubMed ID: 25592566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic assessment of analytical methods for drug sensitivity prediction from cancer cell line data.
    Jang IS; Neto EC; Guinney J; Friend SH; Margolin AA
    Pac Symp Biocomput; 2014; ():63-74. PubMed ID: 24297534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deciphering mechanisms of response and resistance in large-scale mouse cancer screens.
    Prahallad A; Jensen MR; Chapeau EA
    Curr Opin Genet Dev; 2019 Feb; 54():48-54. PubMed ID: 30954760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standardized high-throughput evaluation of cell-based compound screens.
    Frommolt P; Thomas RK
    BMC Bioinformatics; 2008 Nov; 9():475. PubMed ID: 19014471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotype-driven chemical screening in zebrafish for compounds that inhibit collective cell migration identifies multiple pathways potentially involved in metastatic invasion.
    Gallardo VE; Varshney GK; Lee M; Bupp S; Xu L; Shinn P; Crawford NP; Inglese J; Burgess SM
    Dis Model Mech; 2015 Jun; 8(6):565-76. PubMed ID: 25810455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Target Discovery for Precision Medicine Using High-Throughput Genome Engineering.
    Guo X; Chitale P; Sanjana NE
    Adv Exp Med Biol; 2017; 1016():123-145. PubMed ID: 29130157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are CRISPR Screens Providing the Next Generation of Therapeutic Targets?
    Vazquez F; Sellers WR
    Cancer Res; 2021 Dec; 81(23):5806-5809. PubMed ID: 34853037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.